Patent application number | Description | Published |
20090057549 | Method of Excising Sugar Chain from Glycoprotein, Method of Mass Spectrometry of Sugar Chain, and Method of Mass Spectrometry of Glycoprotein - The present invention provides a method of enzymatic reaction on a membrane by a sugar chain releasing enzyme, for an MALDI-TOF MS analysis of a glycoprotein that is solid-phased on a membrane is conducted directly on the membrane; a method of mass spectrometry of a sugar chain in which a sugar chain, for the MALDI-TOF MS analysis of a sugar chain excised from a glycoprotein that is solid-phased on a membrane is conducted directly on the membrane; and a method of mass spectrometry of a glycoprotein, for the MALDI-TOF MS analysis of a glycoprotein of a glycoprotein that is solid-phased on a membrane is conducted directly on the membrane. A method of excising a sugar chain to obtain excised sugar chains by excising the sugar chains by dispensing a sugar chain releasing enzyme solution on a glycoprotein that is solid-phased on a carrier, wherein the sugar chain releasing enzyme solution is a solution containing a sugar chain releasing enzyme in a reaction buffer solution containing a buffering agent consisting essentially of a volatile component. A method of mass spectrometry of a sugar chain and a method of mass spectrometry of a glycoprotein using the method of excising the sugar chain. | 03-05-2009 |
20090197273 | NOVEL N-ACETYLGALACTOSAMINE TRANSFERASES AND NUCLEIC ACIDS ENCODING THE SAME - An enzyme which transfers N-acetylgalactosamine to N-acetylglucosamine via a β1-4 linkage was isolated and the structure of its gene was explained. This led to the production of said enzyme or the like by genetic engineering techniques, the production of oligosaccharides using said enzyme, and the diagnosis of diseases on the basis of said gene or the like. | 08-06-2009 |
20090216705 | METHOD FOR PREDICTING SUGAR CHAIN STRUCTURE - An object of the present invention is to provide a method for conveniently analyzing sugar chain (isomer) structure using a sample of approximately 1 picomole, which is generally subjected to analysis in proteomics without using any sugar chain preparation. The present invention relates to a method for analyzing sugar chain structure, comprising a step of obtaining the fragmentation pattern of a test sugar chain through fragmentation of the test sugar chain and a step of predicting the structure of the test sugar chain through comparison of the sugar chain predicted fragmentation pattern data generated based on fragmentation pattern templates with the fragmentation pattern of the test sugar chain. | 08-27-2009 |
20110059466 | SUPPORT FOR ELECTROPHORESIS INCLUDING HYDROPHOBIC POLYMER MEMBRANE, AND ELECTROPHORETIC SEPARATION METHOD USING THE SAME - There is provided a membrane electrophoresis which renders possible glycan analysis of polysaccharide and glycoprotein by separating protein, glycoprotein or polysaccharide by electrophoresis, followed by carrying out a glycan-releasing treatment of the membrane used in the electrophoresis, or a membrane electrophoresis which renders possible detection of the same by an immunostaining which uses an antibody, wherein a layer containing a hydrophilic polymer is formed on a hydrophobic polymer membrane by coating the hydrophilic polymer on the whole surface of the hydrophobic polymer membrane or by soaking the hydrophobic polymer membrane in a solution of the hydrophilic polymer, which is used as a substrate for electrophoresis. | 03-10-2011 |
20120065089 | Method For Detecting And Distinguishing Intrahepatic Cholangiocarcinoma - Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit therefor. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision. | 03-15-2012 |
20120172247 | Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, and glycan-marker glycoprotein as an index for clinical conditions of liver disease - An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP. | 07-05-2012 |
20120190576 | Glycan Markers as Measure of Disease State of Hepatic Diseases - The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states. | 07-26-2012 |
20130288272 | LUNG CANCER DIFFERENTIAL MARKER - An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers. | 10-31-2013 |
20140057286 | Method for Measuring Glycoprotein, Method for Examining Liver Desease, Reagent for Quantitative Determination of Glycoprotein and Glycan-Marker Glycoprotein as an Index for Clinical Conditions of Liver Disease - An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured. | 02-27-2014 |
20140066617 | METHOD FOR PRODUCING SIALIC-ACID-CONTAINING SUGAR CHAIN - [Problem to be Solved] | 03-06-2014 |
20140242607 | ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER - It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-β1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1. | 08-28-2014 |
20140295455 | ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER - The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-β1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1. | 10-02-2014 |
20140315246 | COMPOSITE SUGAR CHAIN HYDROLASE - The present invention provides a novel endo-β-N-acetylglucosaminidase (Endo-Om) using a transformant produced by cloning an endo-β-N-acetylglucosaminidase (Endo-Om) gene originated from a methylotrophic yeast | 10-23-2014 |